Change theme to redChange theme to blueChange theme to greenChoose your color
 

Technologies Available for Licensing

For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil



COMPOSITIONS CONTAINING FULL-LENGTH L1R NUCLEIC ACID AND ENDOPLASMIC RETICULUM TARGETING SEQUENCE, AND METHODS OF USE

The invention described here encompasses DNA and protein vaccines against poxviruses, and relevant immunogenic compositions, comprising at a minimum a nucleic acid encoding a modified full-length poxvirus L1R gene or its ortholog. The L1R gene is modified so that an endoplasmic reticulum-targeting sequence is operably linked on the 5' end. Preferably the nucleic acid sequences for other poxviruses antigens are also included, such as A33R, B5R and/or A27L. These vaccines and compositions provide improved neutralizing antibody response elicited by molecular poxvirus vaccines, over known vaccines using unmodified L1R.


Docket:RIID 2007-36

Publication/Issued No.:8,513,005

Publication/Issue Date:2013-08-20

Categories: Vaccine

More Detail:Visit USPTO.GOVExternal link

Lab:RIID

Inventor(s):HOOPER, ET AL


For Licensing Opportunities, please contact the ORTA at USArmy.Detrick.MEDCOM-USAMRMC.List.ORTA@mail.mil
 

iSalute

This Web site provides an introduction to the Office of Research and Technology Applications (ORTA) and contains official Government information.

Its use is intended for members of the general public, news media and Military Health System beneficiaries.

Please address questions or concerns about this Web site to the USAMRDC Public Affairs Office at:
usarmy.detrick.medcom-usamrmc.list.webmaster@mail.mil or by telephone at (301)619-2736